Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Procter & Gamble Co.

www.pg.com

Latest From Procter & Gamble Co.

Pharma Q1 Results Preview: Merck & Co, Pfizer, Gilead, Novo Nordisk, Teva, Celgene

Merger appetites and competitive dynamics will continue to be assessed as investors grill the next round of biopharma companies presenting first quarter sales and earnings. Gilead and Pfizer will be particularly pressed on deals.

Sales & Earnings Commercial

Turnaround Lagging, Vitamin Shoppe Heeds Hedge Fund Direction

Shah Capital Management, with 17.7% of Vitamin Shopper shares, and Vintage Capital Management , which owns 14.8%, will appoint three of five replacements to Vitamin Shoppe's board and will have a say in the other two. Vitamin Shoppe also will sell its under-performing contract manufacturing unit and tender, subject to ratification by Shah and Vintage, up to $25m of its common stock at a per-share price not to exceed $5.

International United States

Deal Watch: Fresenius Drops Bid For Akorn, Citing Data-Integrity Concerns

Janssen and Bristol team to develop next-generation oral anticoagulant, while UCB buys Proximagen's nasal spray candidate and Duke spinout focused on genomics.
Business Strategies Deals

Merck KgaA-P&G Deal: Complex In Some Emerging Markets But No ‘Dis-Synergies’

Merck KGaA’s sale of its global consumer health business to Procter & Gamble (P&G) is expected to be a somewhat complex affair in emerging markets like India, where it has a listed entity and a seemingly cohesive consumer health and pharma footprint, though Merck's management emphasized that no “dis-syneries” are anticipated.

M & A India
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register